Biolegend, 100749, Brilliant Violet 785™ anti-mouse CD8a Antibody, 125microl

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Komuczki J, et al. 2019. Immunity. 50:1289. PubMed Belk JA, et al. 2022. Cancer Cell. 40:768. PubMed Deák P, et al. 2022. Cell Rep. 41:111563. PubMed Whyte CE, et al. 2022. Curr Protoc. 2:e589. PubMed Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed Houlder E, et al. 2023. Nat Commun. 14:1863. PubMed Ito M, et al. 2023. Sci Rep. 13:5939. PubMed Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Mancini M, et al. 2021. Sci Rep. 11:21171. PubMed Alam A, et al. 2022. Cancer Cell. 40:153. PubMed Cautivo KM, et al. 2022. Immunity. 55:254. PubMed van Dierendonck XAMH, et al. 2022. Proc Natl Acad Sci U S A. 119:e2114739119. PubMed Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed Kim EH, et al. 2020. Elife. 9:00. PubMed Chen H, et al. 2005. J Immunol. 175:591. PubMed Krummey SM, et al. 2020. Cell Reports. 30(5):1282-1291.e5.. PubMed Martens PJ, et al. 2022. Front Endocrinol (Lausanne). 13:1023264. PubMed Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed Jong RM, et al. 2022. J Immunol. 208:407. PubMed Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed McLane LM, et al. 2021. Cell Reports. 35(6):109120. PubMed Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed Marangoni F, et al. 2021. Cell. . PubMed Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed Wei H, et al. 2016. J Immunol. 196: 3537 - 3541. PubMed Gao J et al. 2016. Cell. 167(2):397-404 . PubMed Fang F, et al. 2022. JCI Insight. 7:. PubMed Stump CT, et al. 2021. Open Biol. 11:210245. PubMed Canton J, et al. 2021. Nat Immunol. 22:140. PubMed Mamedov MR, et al. 2018. Immunity. 48:350. PubMed Li J, et al. 2018. Immunity. 49:178. PubMed Poillet-Perez L, et al. 2020. Nat Cancer. 1:923. PubMed Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed Milner JJ, et al. 2020. Immunity. 52(5):808-824.e7. PubMed Glassman CR, et al. 2021. eLife. 10:00. PubMed Lee DH, et al. 2019. PLoS One. 14:e0215727. PubMed Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed Gordon E, et al. 2015. Proc Natl Acad Sci U S A. 112: 13075 - 13080. PubMed Devi S, et al. 2021. Immunity. 54(6):1219-1230.e7. PubMed Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed Kuhn JA, et al. 2021. Elife. 10:. PubMed Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed Brown SM et al. 2017. Endocrinology. 158(10):3592-3604 . PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Tran C, et al. 2017. J Immunol. 10.4049/jimmunol.1600396. PubMed Beura LK, et al. 2018. Immunity. 48:327. PubMed Zhang W, et al. 2022. Nat Methods. 19:759. PubMed Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed Kumagai S, et al. 2020. Immunity. 53(1):187-203.e8. PubMed Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed Dotsey E, et al. 2017. Sci Rep. 7:42584. PubMed Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed Limbach K, et al. 2017. Malar J. 10.1186/s12936-017-1911-z. PubMed Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed Cowan J, et al. 2016. Cell Rep. 14:1041-1048. PubMed Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed Molgora M, et al. 2020. Cell. 182:886. PubMed Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed Staffas A et al. 2018. Cell host & microbe. 23(4):447-457 . PubMed Walsh CM, et al. 2019. Elife. 8:e48448. PubMed Zhu G, et al. 2022. Front Microbiol. 12:806902. PubMed Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed Poillet–Perez L, et al. 2018. Nature. 563:569. PubMed Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed Albaghdadi AJH, et al. 2019. Sci Rep. 9:6528. PubMed Deasy SK, et al. 2019. PLoS Genet. 15:e1008020. PubMed Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID: AB_11218801 (BioLegend Cat. No. 100749) AB_2562610 (BioLegend Cat. No. 100750)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ